Of note, when DLBCL patients were classified in terms of involved sites, extranodal involvement group had higher expression of both JAM-A gene and JAM-A protein in tumor samples (P = 0.0051 and P = 0.0342, Fig. 1D). The gene discussed is F11R; the disease is diffuse large B-cell lymphoma.